Phase 2b study of evocalcet (KHK7580), a novel calcimimetic, in Japanese patients with secondary hyperparathyroidism undergoing hemodialysis: A randomized, double-blind, placebo-controlled, dose-finding study

BACKGROUND: Evocalcet has been developed as a new calcimimetic agent for hemodialysis (HD) patients with secondary hyperparathyroidism (HDSHPT), eliciting fewer gastrointestinal symptoms and drug interactions. We evaluated the efficacy, safety, and optimal starting dose of evocalcet in HDSHPT. METHO...

Descripción completa

Detalles Bibliográficos
Autores principales: Akizawa, Tadao, Shimazaki, Ryutaro, Fukagawa, Masafumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209414/
https://www.ncbi.nlm.nih.gov/pubmed/30379826
http://dx.doi.org/10.1371/journal.pone.0204896

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6209414/
https://www.ncbi.nlm.nih.gov/pubmed/30379826
http://dx.doi.org/10.1371/journal.pone.0204896

Ejemplares similares